These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30252593)

  • 1. Serum level of interleukin 36 in patients with multiple sclerosis.
    Alsahebfosoul F; Jahanbani-Ardakani H; Ghavimi R; Sedaghat N; Etemadifar M
    J Immunoassay Immunochem; 2018; 39(5):558-564. PubMed ID: 30252593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica.
    Farrokhi M; Rezaei A; Amani-Beni A; Etemadifar M; Kouchaki E; Zahedi A
    Acta Neurol Belg; 2015 Dec; 115(4):609-14. PubMed ID: 26008726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine.
    Naderi S; Hejazi Z; Shajarian M; Alsahebfosoul F; Etemadifar M; Sedaghat N
    J Immunoassay Immunochem; 2016; 37(6):659-70. PubMed ID: 27249307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Serum Levels of IL-33, IL-37, Soluble Form of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Circulatory Frequency of VEGFR2-expressing Cells with Multiple Sclerosis Severity.
    Kouchaki E; Tamtaji OR; Dadgostar E; Karami M; Nikoueinejad H; Akbari H
    Iran J Allergy Asthma Immunol; 2017 Aug; 16(4):329-337. PubMed ID: 28865413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate receptor alpha autoantibodies in the serum of patients with relapsing-remitting multiple sclerosis (RRMS).
    Mashayekhi F; Hadipour E; Shabani S; Salehi Z
    Clin Neurol Neurosurg; 2024 Feb; 237():108161. PubMed ID: 38325038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-23 plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects.
    Shajarian M; Alsahebfosoul F; Etemadifar M; Sedaghat N; Shahbazi M; Firouzabadi FP; Dezashibi HM
    Immunol Invest; 2015; 44(1):36-44. PubMed ID: 25083738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.
    Lalive PH; Kreutzfeldt M; Devergne O; Metz I; Bruck W; Merkler D; Pot C
    J Neuroinflammation; 2017 Jul; 14(1):144. PubMed ID: 28738904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progression.
    Badihian S; Shaygannejad V; Soleimani P; Mirmosayyeb O; Samee Z; Manouchehri N; Esmaeil N
    J Biol Regul Homeost Agents; 2018; 32(5):1249-1253. PubMed ID: 30334421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis.
    Farrokhi M; Saadatpour Z; Fadaee E; Saadatpour L; Rezaei A; Moeini P; Amani Beni A
    Iran J Allergy Asthma Immunol; 2016 Dec; 15(6):536-546. PubMed ID: 28129686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
    Gresle MM; Liu Y; Dagley LF; Haartsen J; Pearson F; Purcell AW; Laverick L; Petzold A; Lucas RM; Van der Walt A; Prime H; Morris DR; Taylor BV; ; Shaw G; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1209-13. PubMed ID: 24639436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between interleukin-32 polymorphism and multiple sclerosis.
    Morsaljahan Z; Rafiei A; Valadan R; Abedini M; Pakseresht M; Khajavi R
    J Neurol Sci; 2017 Aug; 379():144-150. PubMed ID: 28716229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution.
    Laplaud DA; Ruiz C; Wiertlewski S; Brouard S; Berthelot L; Guillet M; Melchior B; Degauque N; Edan G; Brachet P; Damier P; Soulillou JP
    Brain; 2004 May; 127(Pt 5):981-95. PubMed ID: 14985265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients.
    Bartosik-Psujek H; Stelmasiak Z
    J Neural Transm (Vienna); 2005 Jun; 112(6):797-803. PubMed ID: 15480850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis influences on the augmentation of serum Klotho concentration.
    Ahmadi M; Emami Aleagha MS; Harirchian MH; Yarani R; Tavakoli F; Siroos B
    J Neurol Sci; 2016 Mar; 362():69-72. PubMed ID: 26944121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
    Kallaur AP; Oliveira SR; Colado Simão AN; Delicato de Almeida ER; Kaminami Morimoto H; Lopes J; de Carvalho Jennings Pereira WL; Marques Andrade R; Muliterno Pelegrino L; Donizete Borelli S; Kaimen-Maciel DR; Reiche EM
    Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis.
    Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K
    JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prolactin level in patients with multiple sclerosis: a case control study.
    Harirchian MH; Sahraian MA; Shirani A
    Med Sci Monit; 2006 Apr; 12(4):CR177-80. PubMed ID: 16572053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.